LT2589602T - Dengė viruso vakcinos komponentų gavimas - Google Patents

Dengė viruso vakcinos komponentų gavimas

Info

Publication number
LT2589602T
LT2589602T LTEP12182319.9T LT12182319T LT2589602T LT 2589602 T LT2589602 T LT 2589602T LT 12182319 T LT12182319 T LT 12182319T LT 2589602 T LT2589602 T LT 2589602T
Authority
LT
Lithuania
Prior art keywords
development
dengue virus
virus vaccine
vaccine components
components
Prior art date
Application number
LTEP12182319.9T
Other languages
English (en)
Inventor
Stephen S. Whitehead
Joseph E. Blaney
Brian R. Murphy
Lai Ching-Juh
Original Assignee
The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health filed Critical The Government Of The U.S.A., As Repr. By The Secretary, Dept. Of Health & Human Services, The Nat. Inst. Of Health
Publication of LT2589602T publication Critical patent/LT2589602T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEP12182319.9T 2006-08-15 2007-08-15 Dengė viruso vakcinos komponentų gavimas LT2589602T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83772306P 2006-08-15 2006-08-15

Publications (1)

Publication Number Publication Date
LT2589602T true LT2589602T (lt) 2016-10-10

Family

ID=39083099

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP12182319.9T LT2589602T (lt) 2006-08-15 2007-08-15 Dengė viruso vakcinos komponentų gavimas

Country Status (15)

Country Link
US (8) USRE46042E1 (lt)
EP (2) EP2589602B1 (lt)
CN (2) CN103602689B (lt)
AU (1) AU2007285929B2 (lt)
BR (2) BRPI0716455A8 (lt)
CA (2) CA3004991C (lt)
CY (1) CY1118003T1 (lt)
DK (2) DK2054428T3 (lt)
ES (1) ES2585553T3 (lt)
HU (1) HUE029333T2 (lt)
LT (1) LT2589602T (lt)
PL (1) PL2589602T3 (lt)
PT (1) PT2589602T (lt)
SI (1) SI2589602T1 (lt)
WO (1) WO2008022196A2 (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339011B1 (en) * 2002-01-10 2015-04-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES West Nile virus and Dengue 4 virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
CA2483653C (en) 2002-05-03 2014-10-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
CA3004991C (en) 2006-08-15 2022-08-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of dengue virus vaccine components
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
MY184428A (en) * 2009-06-01 2021-04-01 Inviragen Inc Compositions and methods for administration of vaccines against dengue virus
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
PL3539565T3 (pl) * 2013-03-15 2023-09-25 Takeda Vaccines, Inc. Kompozycje i sposoby dla konstruktów chimerycznych wirusa dengi w szczepionkach
CN105246506A (zh) 2013-06-21 2016-01-13 默沙东公司 登革病毒疫苗组合物及其使用方法
US10398768B2 (en) * 2014-11-02 2019-09-03 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
SG11201704942QA (en) * 2014-12-22 2017-07-28 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
DE202016008300U1 (de) 2015-07-02 2017-07-14 PrimeVax Immuno-Oncology, Inc. Zusammensetzungen zur Kombinationstherapie mit Denguevirus und dendritischen Zellen
EP3865150A1 (en) 2015-09-26 2021-08-18 Primevax Immuno-Oncology, Inc. Combination therapy with dengue virus and dendritic cells
US11123420B2 (en) * 2015-09-30 2021-09-21 Panacea Biotec Limited Stable live attenuated recombinant dengue vaccine
JP2019511221A (ja) 2016-03-11 2019-04-25 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱毒化された生ジカウイルスワクチン
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
WO2018129202A1 (en) * 2017-01-04 2018-07-12 PrimeVax Immuno-Oncology, Inc. Compositions and methods for therapy with dengue virus
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
BR112019016309A2 (pt) * 2017-02-14 2020-03-31 The Board Of Regents Of The University Of Texas System Vírus da zika atenuado vivo com deleção 3'utr, vacina contendo o mesmo e uso da mesma
US10240130B2 (en) 2017-02-15 2019-03-26 The Board Of Regents Of The University Of Texas System CDNA clone-launched platform for high-yield production of inactivated zika virus
CN111447947B (zh) 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
AU2020331884A1 (en) 2019-08-16 2022-03-03 Takeda Vaccines, Inc. Methods for preventing dengue and Hepatitis A
US20240131197A1 (en) * 2021-02-26 2024-04-25 Duke University Compositions For and Methods of Improving Gene Therapy
WO2023161715A1 (en) * 2022-02-22 2023-08-31 Futr Bio Ltda. Next generation mrna vaccines

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
CA2483653C (en) * 2002-05-03 2014-10-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
EP1761277A1 (en) * 2004-06-14 2007-03-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES West nile viruses with mutations in the 3' terminal stem and loop secondary structure for use as live virus vaccines
CA3004991C (en) * 2006-08-15 2022-08-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of dengue virus vaccine components

Also Published As

Publication number Publication date
US10160957B2 (en) 2018-12-25
EP2589602A2 (en) 2013-05-08
US11332722B2 (en) 2022-05-17
CN103602689A (zh) 2014-02-26
BR122020023372B1 (pt) 2021-11-30
AU2007285929B2 (en) 2013-09-05
CY1118003T1 (el) 2017-05-17
US9090873B2 (en) 2015-07-28
DK2054428T3 (da) 2013-08-26
EP2054428B1 (en) 2013-06-05
ES2585553T3 (es) 2016-10-06
AU2007285929A1 (en) 2008-02-21
US20180171308A1 (en) 2018-06-21
PT2589602T (pt) 2016-07-13
CA2661296C (en) 2018-06-26
HUE029333T2 (en) 2017-03-28
CA2661296A1 (en) 2008-02-21
US10724007B2 (en) 2020-07-28
EP2589602A3 (en) 2013-10-09
PL2589602T3 (pl) 2016-11-30
EP2054428B9 (en) 2013-11-13
CN103602689B (zh) 2016-08-24
CA3004991C (en) 2022-08-30
AU2007285929A2 (en) 2009-04-23
EP2054428A2 (en) 2009-05-06
US20130089567A1 (en) 2013-04-11
SI2589602T1 (sl) 2016-08-31
US8337860B2 (en) 2012-12-25
CN101657463A (zh) 2010-02-24
US20100104598A1 (en) 2010-04-29
US20190119654A1 (en) 2019-04-25
WO2008022196A2 (en) 2008-02-21
CA3004991A1 (en) 2008-02-21
US11746335B2 (en) 2023-09-05
US20240084269A1 (en) 2024-03-14
CN101657463B (zh) 2013-09-18
BRPI0716455A8 (pt) 2019-01-15
EP2589602B1 (en) 2016-04-06
US20220251521A1 (en) 2022-08-11
DK2589602T3 (en) 2016-07-25
BRPI0716455A2 (pt) 2014-03-04
WO2008022196A3 (en) 2009-03-12
US20200318083A1 (en) 2020-10-08
USRE46042E1 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
SI2589602T1 (sl) Razvoj sestavin cepiva proti virusu denge
NO2021010I1 (no) telostritat ethyl
HRP20160410T8 (hr) Inhibitori hepatitis c virusa
EP2091528A4 (en) METHOD FOR INACTIVATING VIRUSES
ZA201004688B (en) Novel vaccines against multiple subtypes of dengue virus
ATE450271T1 (de) Impfstoff
IL196024A0 (en) Influenza vaccine
IL189329A0 (en) Vaccination against dengue virus infection
CR10571A (es) Vacuna virica recombinante
DE602007003533D1 (de) Karosserierahmenbauteil
BRPI0718548A2 (pt) Estabilização de vacinas por liofilização
PT2422810E (pt) Vacina da gripe
EP2091960A4 (en) PEPTIDE VACCINE AGAINST INFLUENZA VIRUS
ZA200809056B (en) Influenza virus vaccine
EP2054081A4 (en) VACCINE AGAINST THE JC VIRUS
ZA200802176B (en) Vaccination against dengue virus infection
ZA200900062B (en) Influenza vaccine
HUS1500008I1 (hu) Hepatitis C vírus inhibitorok
GB0623865D0 (en) Influenza vaccine
GB0623218D0 (en) Influenza vaccine
GB0625453D0 (en) Influenza vaccine
GB0618195D0 (en) Influenza vaccine
GB0619090D0 (en) Influenza vaccine
CN300798843S (zh) 手持搅拌器(ha-3062)
GB0605333D0 (en) Treatment of influenza